Therapy Areas: Oncology
Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184
28 July 2026 - Clinical-stage, AI-native biopharma company Lantern Pharma Inc (NASDAQ:LTRN) said on Tuesday that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 cl...
DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development
28 July 2026 - Generic pharmaceuticals manufacturer DifGen Pharmaceuticals LLC announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Dr...
Harbour BioMed and Sinopharm establish innovation R&D consortium
27 July 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) declared on Monday that it has entered into a strategic collaboration with China National Pharmaceutical Group Co Ltd (Sinopharm) ...
CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer
24 July 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recom...
Active Biotech doses first patient in amended tasquinimod myelofibrosis study
24 July 2026 - Swedish biotechnology company Active Biotech AB (STO:ACTI) announced on Friday that the first patient has been dosed in the amended Phase Ib/II clinical study of tasquinimod in patients...
Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013
24 July 2026 - Commercial-stage pharmaceutical company Bio-Thera Solutions Ltd (SH:688177) announced on Thursday that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug ...